{"nctId":"NCT02811263","briefTitle":"High-dose Erythropoietin for Asphyxia and Encephalopathy","startDateStruct":{"date":"2017-01","type":"ACTUAL"},"conditions":["Neonatal Encephalopathy","Birth Asphyxia"],"count":500,"armGroups":[{"label":"Erythropoietin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Erythropoietin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal saline placebo"]}],"interventions":[{"name":"Normal saline placebo","otherNames":["NS"]},{"name":"Erythropoietin","otherNames":["Epogen"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* ≥ 36 weeks of gestational age\n* Receiving active or passive whole body cooling/hypothermia since \\< 6 hours of age\n* Perinatal depression based on at least one of the following:\n\n  1. Apgar score \\< 5 at 10 minutes, or\n  2. Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP), or\n  3. pH \\< 7.00 in cord gas (arterial or venous) or in an infant gas (arterial or venous) obtained at \\< 60 minutes of age, or\n  4. Base deficit ≥ 15 mmol/L in cord gas (arterial or venous) or in an infant gas (arterial or venous) obtained at \\< 60 minutes of age\n* Moderate to severe encephalopathy (based on modified Sarnat exam) present between 1-6 hours after birth\n\nExclusion Criteria:\n\n* Study drug unlikely to be administered within 26 hours of birth\n* Infant has living twin (or higher order multiple) who is also being cooled\n* Birth weight \\< 1800 g (e.g., intrauterine growth restriction)\n* Genetic or congenital condition that affects neurodevelopment or requires multiple surgeries (e.g., congenital viral infection, hydrops, complex congenital heart disease, severe dysmorphic features, etc.)\n* Head circumference \\< 30 cm\n* Redirection of care is being considered due to moribund condition\n* Patient anticipated to be unavailable for evaluation at age 2\n* Polycythemia (hematocrit \\> 65.0%)\n* Parents/legal guardians with diminished capacity and autonomy\n* Infant is participating or intends to participate in another interventional study during the birth hospitalization (note: does not include observational studies)\n* Sentinel event and encephalopathy occurred only after birth\n* Unable to consent in primary language of parent(s)","healthyVolunteers":false,"sex":"ALL","maximumAge":"24 Hours","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Death or Neurodevelopmental Impairment","description":"Neurodevelopmental impairment defined as any of the following: a) Gross Motor Function Scale (GMFCS) level ≥ 1, or b) GMFCS = 0 or 0.5 and cerebral palsy (CP) (any type), or c) Bayley III Cognitive Score \\< 90","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cerebral Palsy (CP) and Number of Participants With Each Type of Cerebral Palsy (CP), Determined Using a Standardized Neurologic Examination","description":"Neurologic diagnoses: no CP, diparetic CP, hemiparetic CP, quadriparetic CP","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"173","spread":null}]},{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Each Level of Gross Motor Function, Determined Using the GMFCS","description":"Gross Motor Function Scale (GMFCS) is a scale from 0-5, with higher values representing worse outcomes.\n\n* Level 0: Walks 10 steps independently with symmetrical gait\n* Level 0.5: Walks 10 steps independently without symmetrical gait\n* Level 1: Sits. Hands free for play, and creeps or crawls on hands and knees, pulls to stand; cruises or walks with hands held\n* Level 2: Uses hands for sitting support; creeps on stomach or crawls, may cruise/pull to stand\n* Level 3: Sits with external support for lower trunk; rolls, creeps on stomach\n* Level 4: Good head control in supported sitting; can roll to supine, may roll to prone\n* Level 5: Unable to maintain anti-gravity head and trunk postures in prone or sitting; little or no voluntary movement.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null},{"groupId":"OG001","value":"178","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Bayley III Cognitive Score","description":"The Bayley III cognitive score is a population normed score. 100 indicates the population mean with a standard deviation of 15; higher scores indicate a higher level of development.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":"15.7"},{"groupId":"OG001","value":"89.5","spread":"17.5"}]}]}]},{"type":"SECONDARY","title":"Bayley III Language Score","description":"The Bayley III language score is a population normed score. 100 indicates the population mean with a standard deviation of 15; higher scores indicate a higher level of development.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":"20.4"},{"groupId":"OG001","value":"86.7","spread":"20.8"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Epilepsy","description":"≥ 2 afebrile, unprovoked seizures","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Behavioral Abnormalities Determined by the Externalizing Score of the Child Behavior Checklist","description":"Score for externalizing problems on Childhood Behavior Checklist of \\>= 65","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants at Each Level of Severity of Impairment [(1) Normal, (2) Mild Motor and/or Cognitive Impairment, (3) Moderate/Severe Motor and or Cognitive Impairment, (4) Death], Compared Between the Epo and Placebo Groups.","description":"Mild impairment: GMFCS=1 and no cerebral palsy, or GMFCS\\<=0.5 and hemiplegic or diplegic cerebral palsy.\n\nModerate/severe impairment: GMFCS=1 and cerebral palsy, GMFCS \\>=2, quadriplegic cerebral palsy, or Bayley III cognitive score \\<85.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"112","spread":null}]},{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"59","spread":null}]},{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Rates of Epo-related Adverse Events","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Rates of Epo-related Adverse Events","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Serial Circulating Biomarkers of Inflammation/Brain Injury","description":"Epo level at baseline, day 2, and day 4.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":null},{"groupId":"OG001","value":"36.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1530","spread":null},{"groupId":"OG001","value":"34.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2682","spread":null},{"groupId":"OG001","value":"20.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MR Evidence of Brain Injury - Brain Injury Score","description":"Global brain injury scores were calculated using a validated scoring system for HIE. The extent of injury was recorded (i.e., none = 0, \\<25% = 1, 25-50% = 2; \\>50% = 3) as seen on T1, T2, and apparent diffusion coefficient (ADC) images in 8 regions of the brain: caudate, putamen/globus pallidus, thalamus, posterior limb of t he internal capsule (PLIC), cortex, white matter, brainstem, and cerebellum. The severity of brain injury was determined from the global injury score as follows: none (global injury score = 0), mild (1-11), moderate (12-32), or severe (33-138).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With MR Evidence of Brain Injury - Severity of Brain Injury","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"51","spread":null}]},{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"86","spread":null}]},{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"51","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Experiencing Hearing Impairment Requiring Hearing Aids, Per Parent/Caregiver Report, Compared Between the Epo and Placebo Groups.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Experiencing Cortical Visual Impairment, Per Parent/Caregiver Report, Compared Between the Epo and Placebo Groups.","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":137,"n":257},"commonTop":["Ever intubated","Acute liver injury","Thrombocytopenia","Seizure: clinical or electrographic","Hypotension warranting inotropes"]}}}